Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for ProPhase Labs Inc. (PRPH:NASDAQ), powered by AI.
ProPhase Labs Inc. is currently trading at $0.10. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for ProPhase Labs Inc. on Alpha Lenz.
ProPhase Labs Inc.'s P/E ratio is -0.0.
“ProPhase Labs Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -188.1%.”
Ask for details →ProPhase Labs Inc. is a diversified health sciences company engaged in various segments of healthcare and diagnostics. The primary function of ProPhase Labs is to develop, manufacture, and market an array of over-the-counter (OTC) consumer healthcare products. The company has a crucial role in the health and wellness sector by providing innovative solutions for common ailments. Notably, ProPhase Labs also operates within the genetic testing and diagnostics space, offering services that cater to growing demands for personalized medicine and preventive healthcare measures. With a significant presence in both consumer products and advanced diagnostic services, ProPhase Labs impacts sectors ranging from retail healthcare to biotechnology. As a company continually expanding its product lines and diagnostic capabilities, ProPhase Labs positions itself as an integral player in fostering accessible health solutions, thereby enhancing its market significance in the dynamic landscape of healthcare innovation and delivery.
“ProPhase Labs Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -188.1%.”
Ask for details →ProPhase Labs Inc. (ticker: PRPH) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 96 employees. Market cap is $298,740.
The current price is $0.1 with a P/E ratio of -0.01x and P/B of 0.04x.
ROE is -188.11% and operating margin is -570.59%. Annual revenue is $7M.